-
Mashup Score: 1The role of immune checkpoint inhibitors (ICI) as adjuvant treatment in renal cell carcinoma (RCC): A Systematic Review and Meta-Analysis - 2 year(s) ago
Renal cell carcinoma (RCC) is the third most common urological malignancy. Worldwide, RCC account as 16th tumor in incidence and mortality with 431,288 and 179,386 new cases and new deaths, respectively, with his incidence rising in the last years1, 2. Most patients are diagnosed with localized and regional disease, with only 15 to 25% of the patients diagnosed as metastatic disease2, 3….
Source: Clinical Genitourinary CancerCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 1The role of immune checkpoint inhibitors (ICI) as adjuvant treatment in renal cell carcinoma (RCC): A Systematic Review and Meta-Analysis - 2 year(s) ago
Renal cell carcinoma (RCC) is the third most common urological malignancy. Worldwide, RCC account as 16th tumor in incidence and mortality with 431,288 and 179,386 new cases and new deaths, respectively, with his incidence rising in the last years1, 2. Most patients are diagnosed with localized and regional disease, with only 15 to 25% of the patients diagnosed as metastatic disease2, 3….
Source: Clinical Genitourinary CancerCategories: Hem/Oncs, Latest HeadlinesTweet-
Outstanding talk by @DrRanaMcKay about adjuvant ICI in #RCC during our tumor board at @hosp_einstein. A controversial therapy based on the last studies, that we discussed in our recently published metaanalysis https://t.co/XJJDlr3gLa @fsabino_onco @fmassari79 @drenriquegrande https://t.co/3pImJisgmw
-
-
Mashup Score: 5The role of immune checkpoint inhibitors (ICI) as adjuvant treatment in renal cell carcinoma (RCC): A Systematic Review and Meta-Analysis - 2 year(s) ago
Pembrolizumab, a PD-1 ICI is approved for the adjuvant treatment of post-nephrectomy patients with clear cell RCC in some countries worldwide. However…
Source: www.sciencedirect.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Happy to share our interesting MA about adjuvant ICI in #RCC, lead by @fsabino_onco. Nice review to help the decision between offer or do not offer adjuvant tx. Thanks @fmassari79 @drenriquegrande and all colleagues, it was a pleasure work with this team https://t.co/ZhLQhzbtWH https://t.co/TwuPYof0b4
-
-
Mashup Score: 2
Pembrolizumab Combined With Cisplatin-based Chemotherapy as First-line Systemic Therapy in Advanced Penile Cancer – Full Text View.
Source: clinicaltrials.govCategories: Hem/Oncs, Latest HeadlinesTweet-
Important data in a neglected tumor. Very soon we’ll have the data from our trial looking at ICI plus chemo in penile cancer https://t.co/YJbfgkKpoD https://t.co/PKCOPYtHjT
-
-
Mashup Score: 0Corinthians 1x0 Santos - 1974 (Despedida do Pelé) - 2 year(s) ago
Melhores momentos da Tv Gazeta do jogo despedida do Pelé, onde o Corinthians ganha de 1×0 gol do Rivelino.Dai o Pelé pra não sair com derrota, fez mais umas …
Source: YouTubeCategories: Hem/Oncs, Latest HeadlinesTweet-
The last match played by @Pele. @Corinthians 1 x 0 @SantosFC. @Corinthians supporters effusively applauded the #kingPele. Increadible picture with @Pele and #Rivelino https://t.co/tviIg667E4 https://t.co/FYrTdL4J8K
-
-
Mashup Score: 2Population, Clinical, and Scientific Impact of National Cancer Institute's National Clinical Trials Network Treatment Studies - 2 year(s) ago
PURPOSE In the United States, the National Cancer Institute National Cancer Clinical Trials Network (NCTN) groups have conducted publicly funded oncology research for 50 years. The combined impact of all adult network group trials has never been systematically examined. METHODS We identified randomized, phase III trials from the adult NCTN groups, reported from 1980 onward, with statistically…
Source: Journal of Clinical OncologyCategories: Hem/Oncs, Latest HeadlinesTweet-
Clinical trials save lifes! Congrats @LACOG_group and all investigators to fight hardly and with minimal funding to improve research in our region. https://t.co/LZkWxvHguQ https://t.co/cBBpOwImmG
-
-
Mashup Score: 4Multicenter database of patients with germ-cell tumors: a Latin American Cooperative Oncology Group Registry (LACOG 0515). - 2 year(s) ago
Germ-cell tumors (GCTs) are the most common malignancy in young men. There is a paucity of data on GCTs in developing countries. LACOG 0515 study aime…
Source: www.sciencedirect.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Oncological data is lacking for the majority of tumors in LATAM. Our group @LACOG_group, lead by @DiogoAssed published the largest cohort of patients with germ-cell tumors treated in Latin America. Are the outcomes comparable to developed countries? https://t.co/UWHSFW3vql
-
-
Mashup Score: 0
Nivolumab, a PD-1 ICI has been recently approved for the adjuvant treatment of high-risk MIUC patients. However, conflicting data from another randomized controlled trial (RCT) with atezolizumab makes the benefit of this treatment uncertain. We performed a systematic review and study-level meta-anal …
Source: PubMedCategories: Hem/Oncs, Latest HeadlinesTweet-
Is there any subgroup of patients who benefit more or should not receive ICI as adjuvant in UC. Why different results between trials. Check out here: https://t.co/XGQiTtACiW https://t.co/8WQHjxTv9m
-
-
Mashup Score: 2
Recently, an informal Twitter survey about the treatment of clinical stage I (CSI) seminoma generated an interesting discussion with many interactions.
Source: ASCO Daily NewsCategories: Hem/Oncs, Latest HeadlinesTweet-
Fully agree: active surveillance is a treatment, and must be recommended for almost every CSI seminoma #ESMO2022 https://t.co/DqukNIl2Hv https://t.co/3dBPUXWnUO
-
-
Mashup Score: 1
Nivolumab, a PD-1 ICI has been recently approved for the adjuvant treatment of high-risk MIUC patients. However, conflicting data from another randomized controlled trial (RCT) with atezolizumab makes the benefit of this treatment uncertain. We performed a systematic review and study-level meta-anal …
Source: PubMedCategories: Hem/Oncs, Latest HeadlinesTweet-
I’ll add that for UTUC who did not receive NACT, platinum based chemo (POUT trial), regardless of platinum eligibility, must be the treatment choice, and not nivo https://t.co/XGQiTtACiW https://t.co/t98Xskp3xd
-
Great review, congrats. Our contribution about this intriguing data https://t.co/XJJDlr2IVC @fsabino_onco @fmassari79 @drenriquegrande https://t.co/N3oCS9RZNe